Movetis wins two out of three categories at the PharmaVentures European Deals 2010 Awards
Movetis NV announced that it has won the European Financing Deal of the Year and the European M&A Deal of the Year at the PharmaVentures European Deals 2010 Awards. The awards recognise Movetis’ successful IPO on Euronext Brussels in December 2009, as well as the recent public tender offer by Shire on all outstanding shares and warrants of Movetis. These prestigious awards were presented yesterday night at the Sachs Associates 10th Annual Biotech in Europe Investor Forum in Zurich.
These awards reflect the rapid development and success of Movetis before and since its IPO in 2009. In October last year the Company gained the authorisation to market Resolor for the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief in 30 European countries. This was followed by Movetis’ successful IPO on Euronext Brussels in December 2009 and the commercial launch of Resolor in the first European markets in the first half of 2010. In August 2010, Switzerland became the 31st country where Resolor is approved in a first indication.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Clavis Pharma announces negative outcome of pivotal LEAP Trial with CP-4126 in Patients with Metastatic Pancreatic Cancer

DNA repair: Opening the hatch to heal the break

New drug candidates identified in bacteria - Bacteria show great promise as a source of active ingredients
